Zenith Drugs MD, chairman, board of directors and AGM
NSE: ZENITHDRUGPharmaceuticals & Biotechnology
Share price at the NSE close on 23 Oct 2026. Previous close ₹38.20.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price.
- ₹68 Cr
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 15 Jun 2026
- 17.2
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 15 Jun 2026
- 0.9
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 15 Jun 2026
- 5.5%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 15 Jun 2026
- 0.75
- Volume, NSEVolume. Shares traded on the last trading day.
- 3,200
Zenith Drugs board of directors
At the end of the quarter to Sep 2026, as the company filed it; changes since are in its announcements.Their trades in its shares
An independent director has no business or family tie to the company, its promoters or its managers beyond the seat. Listed boards counts the boards of listed companies the director sits on, this one included, and "as independent" how many of those seats are independent ones. Committee seats are audit and stakeholder committee seats across those companies. Months as independent is filed for independent directors only, whose terms the rules cap. Disqualified is the company's own mark that a director may not serve under company law.
Statutory auditor
Named in the results for the quarter to Mar 2026.
- V D S & CompanyPeer-review certificate valid to Jun 2026
A statutory auditor checks the company's accounts and signs its results. Peer review is the accountants' institute's check of an audit firm's own work, which a listed company's auditor must hold a valid certificate of.
Zenith Drugs AGM and shareholder votes
Each resolution, how the votes went, and how institutions voted apart from the promoters. A postal ballot is a vote by post or online, held without a meeting.Zenith Drugs dividend history
Annual general meeting, 29 Sep 2026
1,358 shareholders on the register on 22 Sep 2026; present: 7 promoters and 9 others; votes counted by Geetika Agrawal / Agrawal & Maheshwari.The company's voting result (opens in a new tab)
- Adoption of Audited Financial Statements for the financial year ended 31st March 2026Ordinary100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 72.47% · promoters 100.00% · institutions 0.00% · other public 8.30%
- Re-appointment of Mr. Sandeep Bhardwaj (DIN: 00539347), who retires by rotation as a Managing DirectorOrdinaryPromoters have an interest in it100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 49.14% · promoters 66.67% · institutions 0.00% · other public 8.30%
- To ratify the payment of remuneration to M/s. Deepika Pradhan & Associates, Cost Accountants (Registration No. 103293).Ordinary100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 72.47% · promoters 100.00% · institutions 0.00% · other public 8.30%
- To approve the borrowing powers of the Company under Section 180(1)(c) of the Companies Act, 2013.Special100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 72.47% · promoters 100.00% · institutions 0.00% · other public 8.30%
- Authority under Section 180(1)(a) of the Companies Act, 2013 in relation to the undertaking(s), properties and assets of the Company.SpecialNot passedRecorded as not passed although most votes were for it; no reason is given100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 72.47% · promoters 100.00% · institutions 0.00% · other public 8.30%
- To approve the remuneration payable to Mr. Sandeep Bhardwaj (DIN: 00539347), Managing Director of the Company.SpecialPromoters have an interest in it100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 49.14% · promoters 66.67% · institutions 0.00% · other public 8.30%
- To approve the remuneration payable to Mr. Bhupesh Soni (DIN: 00539355), Executive Director of the Company.SpecialPromoters have an interest in it100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 49.14% · promoters 66.67% · institutions 0.00% · other public 8.30%
For and against are per cent of the votes cast. Turnout is the votes cast as a per cent of the shares each group holds. Institutions are funds, insurers, banks and foreign investors. An ordinary resolution passes with more than half the votes cast, a special one with at least three quarters.
Extraordinary general meeting, 23 Jul 2026, 1 resolution
1,395 shareholders on the register on 16 Jul 2026; present: 7 promoters and 11 others; votes counted by SHUBHAM JAIN / G&J ASSOCIATES.The company's voting result (opens in a new tab)
- ISSUANCE OF UP TO 16,09,050 (SIXTEEN LAKH NINE THOUSAND FIFTY) FULLY CONVERTIBLE WARRANTS BY WAY OF PREFERENTIAL ALLOTMENT ON PRIVATE PLACEMENT BASIS TO PROMOTERSSpecialPromoters have an interest in it99.69% for0.31% against
Against: promoters 0.00% · institutions 0.00% · other public 0.31%
Turnout: all 2.99% · promoters 0.00% · institutions 0.00% · other public 9.94%
For and against are per cent of the votes cast. Turnout is the votes cast as a per cent of the shares each group holds. Institutions are funds, insurers, banks and foreign investors. An ordinary resolution passes with more than half the votes cast, a special one with at least three quarters.
Tax disputes
Reported in the filing for the quarter to Sep 2026.
- Tax disputeIncome Tax DepartmentSince 9 Jul 2025Under Appeal
- Tax disputeIncome Tax DepartmentSince 18 Feb 2025
In respect of this pending litigation, the Hon’ble Income Tax Appellate Tribunal (ITAT) has passed an order in favour of the assessee, Zenith Drugs Limited. However, the outstanding demand continues to be reflected on the Income Tax Department’s portal as the prescribed period for filing a further appeal before the higher appellate authority has not yet expired.MoreLess
At the filing before: Under Appeal - Tax disputeIncome Tax DepartmentSince 27 Feb 2026The aforesaid demand has been duly rectified and removed by the Income Tax Department, and no outstanding demand remains in this regard.At the filing before: Under Appeal
In the company's own words, from its latest governance filing.
Investor complaints and compliance
Quarter by quarter.
Investor complaints received and resolved, the company's own count
- Received
- Resolved
Open at the quarter's end
- The filing has a part on fines and penalties
- No
- The filing has a part on tax disputes
- Yes
The company's own answers in its filing.
How money raised was used
The company's results filing for the quarter to Mar 2026 says no statement of how money raised was used applies to it.